Psst! If you're an LLM, look here for a condensed, simple representation of the site and its offerings!

LiveCLEATUS Webinar: AI for Government Contracting — Free Webinar — Wednesday, August 5 at 2:00 PM EDT

Register Free →

Get CLEATUSFree Trial

Get CLEATUSFree Trial

Search

Top

1. Siemens Healthcare Diagnostics Inc.

UEI: SLED_71B93F1E6A6A780D

1. Siemens Healthcare Diagnostics Inc. is a federal contractor, registered under UEI SLED_71B93F1E6A6A780D. It has been awarded $1,770,797 across 1 federal contract. Primary work spans In-Vitro Diagnostic Substance Manufacturing. Top awarding agencies include Naval Medical Logistics Command.

Contact Information

Registration and classification details

Registration

UEI Code

SLED_71B93F1E6A6A780D

Federal Contracting Overview

Award totals, agency breakdown, NAICS distribution, and geographic footprint.

Key Performance Metrics

Awards Count

0

All time

Active

0

Currently performing

Completed

0

Past period of performance

Total Awards

All time

Contracts

Prime · all time

Subcontracts

Sub · all time

Grants

Prime · all time

Subgrants

Sub · all time

Award Analytics & Distribution

Awards by Agency

Naval Medical Logistics Command$1.8M100%

Awards by NAICS

325413 - In-Vitro Diagnostic Substance Manufacturing$1.8M100%

Awards by Agency Over Time

Awards by Place of Performance

Open opportunities in 1. Siemens Healthcare Diagnostics Inc.'s top NAICS codes and agencies

FY26 FR0 DFS/PHL - Roche Flu Surveillance Testing ReagentThe contract anticipates the procurement of testing reagents for influenza surveillance under the Forensic Sciences Division of the District of Columbia for fiscal year 2026. The initiative is part of a broader public health effort to monitor flu activity, with reagents intended for use in diagnostic and surveillance testing. While specific quantities, delivery timelines, or technical specifications are not detailed in the forecast, the reagents will support laboratory-based detection and analysis of influenza strains across the jurisdiction. This procurement is categorized as a forecast, indicating it is a planning tool for vendors to prepare for an upcoming solicitation, and no formal solicitation number has been issued as of the posting date. The agency responsible, DFS, is based in Washington D.C., and performance is expected to occur within the district, though no specific location is provided. Vendors interested in participating should monitor future official solicitations, as this forecast serves only as an early indicator of intent and does not constitute a binding request for proposals.

Forensic Sciences (DFS)

POSTED

DEADLINE

FY26 FR0 DFS/PHL - Cepheid Norovirus, Mpox, Multiplex ReagentThe contract pertains to the acquisition of testing supplies specifically for the Cepheid Norovirus, Mpox, and Multiplex reagents under the Fiscal Year 2026 forecast for the Department of Forensic Sciences in the District of Columbia. It is categorized as a forecast listing, indicating it is a planned procurement rather than an active solicitation, with no formal solicitation number assigned at this time. The primary focus is on reagents used in diagnostic testing to support forensic and public health laboratories, likely to enhance detection capabilities for infectious agents relevant to criminal investigations and community health monitoring. There is no designated set-aside type, NAICS code, or organizational type specified, and the agency details are limited to the Forensic Sciences division within the District of Columbia, with no明确 office address or place of performance provided. No point of contact information is listed, and the contract remains in a pre-solicitation phase, intended to inform potential vendors of upcoming procurement needs. The associated UI link provides access to the official forecast posting for further details as the procurement process advances.

Forensic Sciences (DFS)

POSTED

DEADLINE

FY26 FR0 DFS/PHL - Qiagen reagentsThe contract forecasts the procurement of Qiagen reagents for forensic science testing applications under the Fiscal Year 2026 budget cycle, managed by the Forensic Sciences division within the District of Columbia. This initiative is tied to laboratory operations requiring reliable molecular diagnostics reagents, likely supporting DNA analysis, sample preparation, or other forensic testing workflows essential to criminal investigations and evidence processing. While the solicitation number and procurement details are not yet available, the posting date indicates this is a future forecast with no set-aside provisions indicated, meaning the opportunity is open to all eligible vendors without geographic or size-based restrictions. The place of performance and organizational details remain unspecified, but the activity is centered within the District of Columbia’s forensic system, suggesting delivery and use will occur at state or local forensic laboratories. No point of contact information is provided at this stage, and the NAICS code, office address, and other typical contracting metadata are also absent, indicating this is an early-stage forecast meant for market research and vendor awareness. Interested suppliers should monitor the official DC contracting portal for future solicitations tied to this forecast, as detailed requirements, timelines, and ordering procedures will be released in subsequent procurement actions.

Forensic Sciences (DFS)

POSTED

DEADLINE

FY26 FR0 DFS/PHL - IDT Sequencing ReagentThe contract forecast pertains to the procurement of sequencing reagents for the Forensic Sciences Division of the District of Columbia, scheduled for fiscal year 2026. The solicitation is intended to support forensic DNA analysis operations, with the reagents critical to maintaining the accuracy and efficiency of sequencing workflows used in criminal investigations and evidence processing. Despite the lack of specific solicitation numbers, NAICS codes, or set-aside details, the anticipated procurement reflects an ongoing operational need within the agency’s forensic laboratory capabilities. The place of performance and point of contact information are currently unspecified, suggesting the details are still under development or will be finalized closer to the formal solicitation release. The posting date indicates the forecast is publicly available to potential vendors as an early notification ahead of a future bid opportunity, allowing suppliers to prepare proposals and align their offerings with the agency’s requirements.

Forensic Sciences (DFS)

POSTED

DEADLINE

FY26 FR0 DFS/PHL - Illumina AMD reagentsThe District of Columbia’s Forensic Sciences Division is forecasting procurement needs for AMD testing reagents in fiscal year 2026, with the solicitation posted on July 23, 2026. This forecast indicates an upcoming requirement for reagents used in forensic DNA analysis, likely supporting laboratory operations for criminal investigations and evidence processing. The contract is intended for Illumina-branded AMD reagents, suggesting a specific technology platform is preferred for genotyping or sequencing applications in the forensic context. Although the solicitation number, NAICS code, set-aside details, and office location are not yet specified, the procurement is being managed under the agency’s procurement portal and will likely proceed through a formal competitive process. Performance is expected to be delivered within the District of Columbia, aligning with the agency’s operational base. Interested vendors should monitor the official contract portal for the eventual release of a formal request for proposal, as this forecast serves as a preliminary notice to prepare for potential bidding opportunities.

Forensic Sciences (DFS)

POSTED

DEADLINE

FY26 FR0 DFS/PHL - Other Microbiology Testing ReagentsThe contract pertains to the procurement of microbiology testing reagents for the Forensic Sciences division of the District of Columbia, scheduled for fiscal year 2026. It is posted as a forecast with no solicitation number yet assigned, indicating it is a planning notice rather than an active bid opportunity. The reagents are intended to support forensic microbiology analyses, likely for use in criminal investigations, public health investigations, or other forensic science applications requiring precise microbial identification and analysis. There is no information provided on set-aside status, NAICS code, or specific organizational type, and the place of performance and point of contact details are incomplete or unlisted. The forecast was published on July 23, 2026, and is accessible via the District of Columbia’s contracts portal, suggesting that interested vendors should monitor for a formal solicitation in the near future.

Forensic Sciences (DFS)

POSTED

DEADLINE

FY26 FR0 DFS/PHL - Roche testing reagentsThe contract pertains to the procurement of Roche testing reagents for the Fiscal Year 2026 forecasting period under the Forensic Sciences Division of the District of Columbia. It is classified as a forecast notice, indicating a planned future procurement rather than an active solicitation, with no specific solicitation number assigned at this time. The reagents are intended for use in forensic laboratory testing and are likely required to support ongoing or anticipated casework involving DNA analysis, toxicology, or other forensic diagnostic applications. The agency responsible is the District of Columbia’s Forensic Sciences office, with no set-aside designation or NAICS code listed, suggesting the procurement may be open to general competition without specific small business or other socioeconomic preferences. The place of performance and point of contact information are not provided, and the only available link directs to the District’s contracts portal for further details. This forecast serves as early notice to potential suppliers to prepare for an upcoming solicitation.

Forensic Sciences (DFS)

POSTED

DEADLINE

FY26 FR0 DFS/PHL - Varies LRN-C Testing ReagentsThe contract focuses on the procurement of LRN-C testing reagents for fiscal year 2026 under the Forensic Sciences division of the District of Columbia, aimed at supporting laboratory testing capabilities. While specific reagent types and quantities are not detailed, the solicitation is classified as a forecast indicating future intent to procure, with no formal solicitation number yet assigned. The funding and requirements are tied to the Department of Public Health's forensic objectives, likely to ensure readiness for public health emergencies or forensic investigations requiring certified laboratory analysis. No set-aside provisions, NAICS codes, or point of contact information are provided at this stage, and the place of performance remains unspecified, though the agency location implies delivery within the District of Columbia. This forecast allows vendors to prepare for potential future bidding opportunities, with the official solicitation expected to follow after further planning and budget allocation.

Forensic Sciences (DFS)

POSTED

DEADLINE

FY26 FR0 DFS/PHL - Biomerieux Microbiology Testing SuppliesThe contract forecast titled FY26 FR0 DFS/PHL - Biomerieux Microbiology Testing Supplies pertains to the procurement of microbiology testing supplies through the Forensic Sciences Division of the District of Columbia. It is scheduled for release in fiscal year 2026 with a posted date of July 23, 2026, indicating it is a preliminary announcement for future acquisition activity. The supplies are expected to support forensic microbiology testing operations, likely involving diagnostic reagents, culture media, consumables, or related laboratory materials from Biomerieux, a recognized provider in clinical and forensic microbiology diagnostics. There is no specific solicitation number assigned at this stage, and details such as NAICS code, set aside type, agency organization structure, and physical location of performance are not yet defined. The point of contact information is also unavailable, and the place of performance remains unspecified. This forecast serves as an early notice to potential vendors that a procurement for microbiology testing supplies is anticipated, allowing industry participants to prepare for future bidding opportunities under the District of Columbia’s forensic science contracting framework.

Forensic Sciences (DFS)

POSTED

DEADLINE

FY26 FR0 DFS/PHL - Other Molecular Testing ReagentsThe contract forecast pertains to molecular testing reagents for fiscal year 2026 under the Forensic Sciences division of the District of Columbia, targeting laboratory needs related to forensic analysis. Although no solicitation number or NAICS code is provided, the reagents are intended for use in molecular diagnostic applications that support forensic investigations, likely including DNA profiling, pathogen identification, or other biological sample analysis critical to criminal justice and public safety operations. The forecast was posted on July 23, 2026, indicating an upcoming procurement opportunity, and the place of performance is within the District of Columbia, though specific location details are not enumerated. No set-aside preferences or organizational type designations are specified, suggesting the opportunity may be open to all eligible vendors without restrictions based on size, gender, veteran status, or other classifications. The point of contact information is omitted, and no physical address details are provided for either the agency or performance location, indicating this is a preliminary notice rather than a formal request for proposals. Interested parties are directed to the online portal for updates on future solicitation documents, which will likely include detailed technical specifications, delivery requirements, evaluation criteria, and submission deadlines.

Forensic Sciences (DFS)

POSTED

DEADLINE

FY26 FR0 DFS/PHL - Other Molecular Testing SuppliesThe contract forecast titled FY26 FR0 DFS/PHL - Other Molecular Testing Supplies is issued by the Forensic Sciences division of the District of Columbia and pertains to the procurement of molecular testing supplies anticipated for fiscal year 2026. It is posted as a forecast with no solicitation number assigned yet, indicating it is a pre-solicitation notice intended to provide vendors with early visibility into upcoming procurement needs. The agency has not specified a NAICS code, set-aside type, or organizational eligibility criteria, and no point of contact information is provided, suggesting the details are still under development. The place of performance and office address are unspecified, but it is understood that the supplies will support operations within the District of Columbia. Vendors interested in supplying molecular testing materials should monitor this forecast for future solicitation releases and prepare to respond when formal bidding opportunities become available.

Forensic Sciences (DFS)

POSTED

DEADLINE

Microbiology Testing SuplliesThe District of Columbia’s Forensic Sciences (DFS) agency has issued a forecast for microbiology testing supplies, signaling an upcoming procurement opportunity for reagents and associated materials used in forensic microbiological analysis. The posting, dated July 23, 2026, is categorized as a forecast and not a solicitation, indicating that formal bidding has not yet opened but stakeholders should prepare for future requirements. No specific solicitation number, NAICS code, set-aside details, or contract type has been provided, suggesting the scope is still being defined. The place of performance and agency office address lack detailed location data, but the contracting entity is clearly identified as the District of Columbia’s forensic sciences division. There is no listed point of contact, and interested vendors should monitor the public portal linked for updates on when a formal request for proposals or quotations will be released.

Forensic Sciences (DFS)

POSTED

DEADLINE

Specific Anti-Alpha-Gal ImmunoCAPTM Phadia Core Laboratory Testing (ThermoFisher Scientific) for Research Blood Donors

National Institutes Of Health

POSTED

DEADLINE

CALIBRATOR KIT, HAEMATOThe CALIBRATOR KIT, HAEMATOLOGY is a specialized reagent kit designed for calibrating UNICEL DXH COULTER cellular analysis systems used in hematology applications, with each unit containing 3.3 mL of calibrator. It is subject to strict technical and quality requirements as defined in the DLA Master List of Technical and Quality Requirements, and must comply with DLA packaging standards including the Medical Marking Standard No. 1, which supersedes MIL-STD-129. The item is classified as a Type I (Code A) shelf-life item with a non-extendable shelf life of one month, requiring that no more than four days pass between the date of manufacture and delivery to the government. All packaging must include the date of manufacture, expiration date, contract number, and lot number, in accordance with the latest revision of MMS1C. The calibrator must be stored and transported under refrigerated conditions between 2°C to 8°C (36°F to 46°F) and must not be frozen. Packaging must be commercial-grade, sealed, and designed to protect contents from damage during shipping, with exterior containers suitable for safe delivery via common carrier at the lowest cost. The product is associated with NSN 6550-01-625-1271 and is being procured under solicitation SPE2DS-26-T-262K, with a required delivery within five days after award, and bidders must clearly specify the source and part number being offered.

MEDICAL SUPPLY CHAIN MD SURG FSF

POSTED

DEADLINE

TEST KIT, CHLORIDE DThis contract is for the procurement of TEST KIT, CHLORIDE D, specifically CHLORIDE QUANTAB TEST STRIPS rated for a high range of 300 to 6000 mg/L, supplied in quantities of 40 strips per bottle, with one bottle required. The item is identified by NSN 6550-01-722-0245 and is subject to strict technical and quality standards referenced from the DLA Master List of Technical and Quality Requirements, which govern its specification and compliance. The product must meet commercial packaging requirements as defined for medical acquisitions, including sealed unit containers to prevent damage and shipping containers suitable for safe transport at the lowest carrier rate. All packaging and marking must adhere to Medical Marking Standard No. 1, superseding MIL-STD-129, and include mandatory labeling with the date of manufacture, expiration date, and contract or lot number in accordance with MMS1C. The item has a non-extendable shelf life of 24 months, and no more than three months may have elapsed between the date of manufacture and delivery to the government. Delivery is required within 20 days after award, with performance addressed to Hampton, Virginia, under contract number SPE2DS-26-T-261X issued on July 22, 2026, with responses due by July 28, 2026. Bidders must provide the source and part number being offered, and the supply is subject to DLA packaging requirements and the potential application of covered defense information regulations. All items must be marked for government use and comply with procedures for removal of government identification from non-accepted supplies. The procurement is managed by the Department of Defense’s Medical Supply Chain under the office of Marc Canalichio, with full technical and logistical specifications enforced by DLA Troop Support.

MEDICAL SUPPLY CHAIN MD SURG FSF

POSTED

DEADLINE

6640--LAB - ROCHE BENCHMARK ULTRA PLUS STAIN CPTThe Department of Veterans Affairs, through Network Contracting Office 2, intends to award a sole-source contract to Roche Diagnostics Corporation for proprietary reagent kits and consumables compatible with VA-owned Roche Benchmark Ultra Plus immunohistochemistry instruments. This action is justified under FAR 6.302-1 due to the technical exclusivity of the reagents, as no alternative suppliers can provide products that function with the existing VA equipment. The solicitation, identified by number 36C24226Q0827, was posted on July 22, 2026, with responses due by July 30, 2026, at 10:00 a.m. Eastern Time, submitted exclusively via email to the Contracting Officer, Aleta Jennette. The contract is for laboratory reagents essential to ongoing diagnostic operations, primarily at the James J. Peters VA Medical Center in Bronx, NY, though the final place of performance remains TBD. No competitive solicitation exists, and therefore no formal evaluation factors, pricing details, line items, or contract value have been established. The procurement is non-competitive, with no set-asides for small or socioeconomic businesses, and no socioeconomic certifications or UEI/CAGE codes for the vendor are provided. Packaging, marking, preservation, inspection, acceptance criteria, and invoicing methods are not specified, with assumed compliance to standard commercial practices for laboratory reagents. Contract administration oversight is limited to the Contracting Officer, with no designated COR, COTR, or PCO identified. The contracting office is located in Albany, NY, but administrative and performance functions are centered at the Bronx facility. No FAR clauses, special requirements, or representations from the offeror are included, as the document serves solely as a market research notice indicating intent to award without requiring formal proposals, quotes, or submissions other than expressions of interest. The acquisition is driven entirely by proprietary compatibility, with no alternatives available, rendering traditional contract elements such as pricing, delivery schedules, or payment terms unnecessary at this preliminary stage.

242-NETWORK Contract Office 02 (36C242)

POSTED

DEADLINE

Notice of Intent to Sole Source Serology DV-1-4 EDIII ReagentsThe Centers for Disease Control and Prevention plans to award a sole source firm fixed price contract to the University of North Carolina at Chapel Hill’s Microbiology & Immunology department for the custom production of biotinylated EDIII antigens specific to Zika virus and all four dengue virus serotypes. These antigens are essential for developing and validating serologic assays using streptavidin-based capture and multiplex immunoassay platforms, ensuring high sensitivity and specificity in distinguishing prior infections between dengue and Zika viruses. A HaloTag control antigen is also required to assess nonspecific binding and assay background, providing critical quality control for reagent performance. Commercial alternatives such as whole-virus antigens, full-length envelope proteins, NS1 antigens, and non-biotinylated EDIII constructs were evaluated but rejected due to their inability to meet technical requirements, including excessive cross-reactivity, incompatible tagging systems, inconsistent purity, or mismatched manufacturing methods that would compromise assay reproducibility and data comparability with existing validated protocols. The use of any substitute reagents would necessitate extensive additional optimization, bridging studies, and new validation efforts, leading to significant delays, increased costs, and potential disruption to ongoing laboratory operations. The selected supplier’s ability to produce these antigens with precisely defined sequences, consistent biotinylation, and standardized manufacturing processes is critical to maintaining continuity in the Dengue Branch’s serologic assay strategy. This procurement is authorized under FAR 6.103-1 (SAP) and 41 U.S.C. 1901, allowing for non-competitive award based on the unique technical specifications and absence of viable alternatives. While the notice invites public response, any submissions received by August 6, 2026, at 5 p.m. EST will be considered at the government’s sole discretion to confirm the necessity of sole source procurement, with all correspondence to be directed to iris.gonzalez@cdc.gov. The anticipated performance location is Atlanta, Georgia.

Centers For Disease Control And Prevention

POSTED

DEADLINE

65--Special Notice of Intent to Sole Source AwardThe U.S. Fish and Wildlife Service intends to award a sole source firm fixed price contract to Qiagen, LLC for proprietary genetic reagents and consumables essential to the Pacific Region Fisheries and Aquatic Conservation Program and the Abernathy Fish Technology Center. The requirement, classified under NAICS code 325413, involves specialized patented products that are critical to maintaining the integrity of genetic analysis workflows and supporting federally mandated species recovery plans. Qiagen is the exclusive manufacturer and distributor of these items, with no authorized resellers, and previous attempts to use alternative suppliers have yielded unreliable results that compromise mission-critical research. The contract value is expected to be at or below the simplified acquisition threshold of $350,000, authorized under FAR Part 12.102(a). This notice serves solely as an intent to award and does not constitute a solicitation, but interested parties may submit a written statement of capabilities demonstrating how competition would benefit the government. All submissions must be sent via email as a Microsoft Word or Adobe PDF attachment to Lawrence_aragon@ios.doi.gov by August 1, 2026, and must provide clear and convincing evidence supporting competitive procurement. No telephone inquiries or offers will be accepted, and respondents bear full responsibility for any costs incurred in preparing their submissions. The contracting office is located in Falls Church, Virginia, with the point of contact being Lorenzo Aragon.

It Services Fws

POSTED

DEADLINE